Becca Krock, PhD, Product Scientist, 23andMe
Michael Multhaup, PhD, Senior Product Scientist, 23andMe
Come find us on the exhibition floor!
23andMe received FDA clearance to report on the two most common genetic variants influencing what is called MUTYH-associated polyposis (MAP), a hereditary colorectal cancer syndrome.
GeneReviews provides clinically relevant and medically actionable information for inherited conditions in a standardized, journal-style format, covering diagnosis, management and genetic counseling for patients and their families.
Genetics/Genomics Competency Center (G2C2) provides high-quality educational resources for group instruction or self-directed learning in genetics/genomics by healthcare educators and practitioners.
Find a Genetic Counselor assists physicians, patients and genetic counselors in accessing genetic counseling services.
Genetics Home Reference provides consumer-friendly information about the effects of genetic variation on human health.
23andMe Education modules explain key genetics concepts consumers need to know in order to get the most out of 23andMe reports.
23andMe Help Center provides information about reports and tools as well as answers to any frequently asked questions. Customers can also contact our dedicated Customer Care Team here.
23andMe Blog posts relevant content in ancestry, health and traits, 23andMe research, 23andMe customer stories, news and announcements and more.
23andMe supports independent medical education to advance the understanding of genetics in healthcare, engage healthcare professionals in genetics education and enhance healthcare professionals’ readiness for integration of genetics into clinical care. Education grants are awarded in compliance with industry guidelines.
23andMe considers proposals for independent medical education activities, including webinars, grand rounds, online courses, workshops and symposia from eligible healthcare organizations and medical education providers.
Contact healthcaregrants@23andMe.com for more information.
*The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. The relevance of each report varies based on ethnicity. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. Our carrier status reports can be used to determine carrier status, but cannot determine if an individual has two copies of any genetic variant. These carrier reports are not intended to tell an individual anything about risk for developing a disease in the future or anything about the health of a fetus, or newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to diagnose disease, determine medical treatment or medical intervention including whether to take a medication or how much of a medication to take, or tell the user anything about their current state of health. Any diagnostic or treatment decisions must be based on confirmatory prescription testing and/or other information that you determine to be appropriate for your patient, such as additional clinical testing and other risk factors that may affect individual risk and health care. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action.
For important information and limitations regarding other genetic health risk reports and carrier status reports, visit https://www.23andme.com/test-info/.